All In Biotech

Drug Trial Radar · NCT05356195

Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)

A Phase 3 Study to Evaluate the Safety and Efficacy of a Single Dose of CTX001 in Pediatric Subjects With Transfusion-Dependent β-Thalassemia

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

16

Actual

Start

May 3, 2022

Primary completion

Nov 14, 2027

Study completion Nov 14, 2027

Sponsor

Lead sponsor
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
Sponsor type
Industry
Collaborators
CRISPR Therapeutics
First posted
May 2, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).

Conditions

  • Beta-Thalassemia
  • Thalassemia
  • Genetic Diseases, Inborn
  • Hematologic Diseases
  • Hemoglobinopathies

Interventions

  • CTX001Biological

    Administered by intravenous infusion following myeloablative conditioning with busulfan.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants who Achieve Transfusion Independence for at Least 12 Consecutive Months (TI12)Time frame: Up to 24 Months After CTX001 Infusion

Locations

6 sites in 5 countries. Site status is shown where the registry gives one.

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee

  • Hospital for Sick Children - Hematology

    Toronto, Canada

  • University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • St.Mary's Hospital - Children's Clinical Research Facility

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.